Alluvi, previously BI 4744, presents a notable breakthrough in weight management treatment. This dual stimulator targeting both GLP-1 and GIP receptors demonstrates compelling effectiveness in patient assessments, https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/